Royal Bank of Canada’s Global X China Biotech Innovation ETF CHB Stock Holding History

Royal Bank of Canada’s Portfolio CHB Stock Details CHB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-100	Closed	-$1K	–	7823
2023 Q2	$1K	Hold	100	–	–	﹤0.01%	7156
2023 Q1	$1K	Buy	+100	New	+$1K	﹤0.01%	6979

Other funds holding CHB

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada's CHB Position: Q3 2023 in Review

Royal Bank of Canada sold out of Global X China Biotech Innovation ETF (CHB) in Q3 2023, closing a stake of 100 shares — an estimated $1K sold.

Royal Bank of Canada first reported a position in CHB in Q1 2023 and held it in 2 quarters. The position peaked at $1K in Q2 2023. 3 funds tracked by Wall St. Rank hold CHB as of Q3 2023.

Royal Bank of Canada reported no remaining Global X China Biotech Innovation ETF position as of Q3 2023 after selling out during the quarter.
Royal Bank of Canada sold 100 Global X China Biotech Innovation ETF shares in Q3 2023, an estimated $1K.
Royal Bank of Canada first reported a position in Global X China Biotech Innovation ETF in Q1 2023 and held it in 2 quarters.
Royal Bank of Canada's Global X China Biotech Innovation ETF position peaked at $1K in Q2 2023.
3 funds tracked by Wall St. Rank held Global X China Biotech Innovation ETF as of Q3 2023.

Based on Royal Bank of Canada's 13F filing for Q3 2023, filed 14 Nov 2023.